Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Forecasted to Earn Q1 2025 Earnings of ($0.71) Per Share

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at Wedbush issued their Q1 2025 earnings estimates for shares of Zentalis Pharmaceuticals in a report issued on Tuesday, May 7th. Wedbush analyst R. Driscoll forecasts that the company will earn ($0.71) per share for the quarter. Wedbush has a "Neutral" rating and a $15.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($3.72) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals' Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.73) EPS and Q4 2025 earnings at ($0.61) EPS.

Other analysts also recently issued reports about the stock. Stifel Nicolaus cut their price target on shares of Zentalis Pharmaceuticals from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday. HC Wainwright reduced their price target on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $37.14.

Zentalis Pharmaceuticals Stock Performance

ZNTL traded up $0.09 during midday trading on Thursday, reaching $12.52. 592,438 shares of the company were exchanged, compared to its average volume of 781,793. The stock has a market capitalization of $889.05 million, a P/E ratio of -2.74 and a beta of 1.82. Zentalis Pharmaceuticals has a one year low of $9.56 and a one year high of $31.46. The stock's 50-day simple moving average is $13.70 and its 200 day simple moving average is $13.43.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its earnings results on Tuesday, May 7th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.77) by $0.91. The business had revenue of $40.56 million for the quarter, compared to the consensus estimate of $35.00 million. During the same quarter in the previous year, the firm posted ($1.07) EPS.

Insider Transactions at Zentalis Pharmaceuticals

In other news, CFO Melissa B. Epperly sold 2,573 shares of the business's stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $29,435.12. Following the sale, the chief financial officer now directly owns 451,449 shares in the company, valued at $5,164,576.56. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO Melissa B. Epperly sold 2,573 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $11.44, for a total value of $29,435.12. Following the sale, the chief financial officer now owns 451,449 shares of the company's stock, valued at $5,164,576.56. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Diana Hausman sold 3,356 shares of Zentalis Pharmaceuticals stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $12.62, for a total transaction of $42,352.72. Following the completion of the sale, the insider now owns 373,876 shares in the company, valued at $4,718,315.12. The disclosure for this sale can be found here. Insiders sold 7,102 shares of company stock valued at $85,207 over the last quarter. Corporate insiders own 6.10% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its holdings in Zentalis Pharmaceuticals by 132.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company's stock worth $36,000 after buying an additional 1,030 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $38,000. Tower Research Capital LLC TRC boosted its stake in shares of Zentalis Pharmaceuticals by 252.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company's stock worth $55,000 after acquiring an additional 2,589 shares during the period. Exchange Traded Concepts LLC increased its holdings in shares of Zentalis Pharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company's stock worth $91,000 after acquiring an additional 1,519 shares during the last quarter. Finally, OneAscent Financial Services LLC bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at about $156,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.